Académique Documents
Professionnel Documents
Culture Documents
Seizure
journal homepage: www.elsevier.com/locate/yseiz
A R T I C L E I N F O
A B S T R A C T
Article history:
Received 8 March 2013
Received in revised form 9 July 2013
Accepted 10 July 2013
Purpose: Controlled randomized studies recommending the clinical use of lamotrigine in adult
populations with the diagnosis of Juvenile Myoclonic Epilepsy are still lacking. To compare the efcacy
and tolerability of lamotrigine versus valproate in adult patients with JME.
Methods: This was a prospective, randomized, controlled, pragmatic, long-term and open-label
treatment trial. Patients were randomized to use valproate or lamotrigine. The primary end points of
the study were: (1) time from randomization to treatment failure (withdrawal); (2) time from
randomization to seizures remission. Secondary ending points were: (1) frequency of clinically
important adverse events and (2) change in the QOLIE-31 after randomization. The denition of seizure
remission was based on disappearance of all seizure types and EEG discharges.
Results: We found that the time to withdraw treatment after randomization was not signicantly
different in lamotrigine and valproate groups. Long-term seizures freedom was equal in the both groups
of the trial; only 8 (19.1%) patients randomized to lamotrigine and 6 (19.4%) randomized to valproate
were not seizure free after 4 months of treatment. Between 17.03% (lamotrigine) and 35.3% (valproate) of
patients reported adverse reactions at some point in the intention-to treat study (p = 0.07). All subscales
of the QOLIE-31 questionnaire, except that related to side effects of medication, improved more than 5
points with respect to baseline period in both groups
Conclusion: Lamotrigine is effective in adult patients with Juvenile Myoclonic Epilepsy and better
tolerated than valproate, although the incidence of idiosyncratic reactions could be a cause of concern.
2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Keywords:
Juvenile Myoclonic Epilepsy
Treatment
Randomized control trial
Valproate
Lamotrigine
1. Introduction
Juvenile Myoclonic Epilepsy (JME) represents the most
common form of idiopathic generalized epilepsy (IGE).1
JME seizures respond well to antiepileptic drugs (AEDs),
particularly valproate. The SANAD (Standard and New Antiepileptic Drugs) study reported that valproate was the most effective and
best-tolerated rst-line AED for patients with IGE, including JME,
when it was compared to lamotrigine and topiramate (TPM).2
Valproate is the rst-line drug in men with JME, but in female
population, lamotrigine (LTG) is preferred due to the teratogenic
and endocrinologic side effects such as polycystic ovary syndrome
and weight-gain associated to valproate. Recent data suggest that
1059-1311/$ see front matter 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.seizure.2013.07.006
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
847
included in until the moment they were evaluated for the last time
(ITT protocol). Trial design can be seen in Fig. 1.
All patients and two of their relatives were interviewed by
experienced epileptologists concerning seizure types, age at
seizure onset, seizure precipitant factors, possible circadian
rhythm of seizures and previously used medications.
In all the patients where Juvenile Myoclonic Epilepsy was
suspected, a routine 21-channel EEG was obtained, according to
the international 1020 system employing a Medicid EEG digital
machine, at the moment of entering the study and after 2 years of
follow-up. All patients were sleep deprived the night before to EEG
performance. At least 10 min of sleep were recorded in each
patient, which primarily resulted in early sleep stages recording
(stages 1 and 2 of non-REM sleep) and only rarely stage 3 non-REM
sleep was seen. EEG recordings had a mean duration of
approximately 30 min.
Taking into account seizure semiology and the electrographic
pattern obtained, the diagnosis of JME was made by two
epileptologists according to the ILAE criteria.13 Seventy-two
patients (100%) had myoclonic seizures, 45 patients had GTCS
(62.5%) and absence seizures were reported in only 27 (37.5%).
2.4. Inclusion criteria
Patients were included in the study if they had past history of
two or more generalized myoclonic seizures. Tonicclonic or
absence seizures in the previous years were also taken into
Fig. 1. Trail prole. The total number of patients that withdrew from treatment for any reason was 12/31 in the valproate group and 6/41 in the lamotrigine group (differences
between two proportions), p = 0.02.
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
848
Table 1
Guideline for titration of medications during follow-up.
Medication
(dose/weeks) Valproate
Medication (dose/weeks)
Lamotrigine
Week
Week
Week
Week
Week
Week
Week
12
200 mg/3 times/day
Week
13
25 mg single dose
34
400 mg/3 times/day
Week
47
25 mg/times/day
56
600 mg/3 times/day
Week
811
50 mg/2 times/day
78
2000 mg daily
Week
1215
50 mg/3 times/day
910
3000 mg daily
Week
1619
100 mg/times/day
1112
3000 mg daily
Week
2024
250 mg/daily
1314
3000 mg/Daily
Week
2527
300 mg/daily
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
drug because of inadequate seizure control, intolerable sideeffects, or both; whichever was the earliest) and (2) time from
randomization to seizure remission. Secondary end points of the
study were: (1) frequency of clinically important adverse events
and side-effects emerging after randomization, (2) quality of life
outcomes, (3) number of seizures evaluated at 3, 6 and 24 months
after treatment was initiated.
849
All authors had full access to the data and took responsibility for
its integrity and for the accuracy of the data analysis. The
corresponding author had the nal responsibility for the decision
to submit for publication.
2.13. Statistical analysis
q
where q
2.12. Ethics
3. Results
The study was conducted according to the Declaration of
Helsinkis criteria and no funding was received from pharmaceutical companies. The patients gave their informed consent to
participate in the study, which was approved by the local ethics
committees.
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
850
Table 2
Incidence of adverse events leading to drug discontinuation during treatment period in the intention-to-treat population.
Medication
Total
Valproatea
Lamotrigine
Total
9 (12.5)
4 (5.6)
13 (18.1)
22 (30.6)
37 (51.4)
59 (81.9)
31 (43.1)
41 (56.9)
72 (100)
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
851
Table 3
Clinical and demographic characteristics of randomization groups at study entrance.
Clinical and demographic variables
41 (100%)
21 (51.21%)
2 (4.8%)
31 (100%)
18 (58.6)
0 (0%)
8 (19.5%)
15 (36.6)/26 (63.4)
279 159 (150400)/249 179 (150400)
69.5 13.3
6 (19.3)
10 (32.3)/21 (67.4)
1570 345 (9003000)/1550 450 (9002700)
62.9 17.85
p values less than 0.05 are marked with *. ITT means intention to treat analysis.
The total quality of life score in the LTG arm improved 7.3 points
and 12.3 points in the valproate arm after 2-years of follow-up
(Table 6). All subscales of the QOLIE-31 questionnaire except the
subscale related to side effects of medication improved more than
5 points after treatment. On the other hand, there were signicant
differences for the outcome assessed by the response rate in
(energy/fatigability, global quality of life, emotional well-being,
cognition functioning) in the valproate group and in emotional
well-being, energy/fatigability in the LTG group (Fig. 3B and C). The
subscale side effects of medication worsened in both groups
because the patients had not been taking these drugs at the
starting point and this subscale had been scored as 100. There were
no signicant differences in the remaining subscales between the
scores at the starting point and at the end of follow-up, between
both study groups.
4. Discussion
Valproate is considered the rst line antiepileptic drug for
patients with Juvenile Myoclonic Epilepsy (JME). Three other
antiepileptic drugs have been employed (levetiracetam, topiramate and zonisamide), which are also said to be effective in
generalized epilepsies.2,5
In developing countries, many of the above mentioned
medications are not part of the therapeutic approach,1720 because
of their high cost and poor availability; but lamotrigine is available
in our country. Thus, our study constitutes a good example of the
therapeutic scenarios that mirror what happens in other developing countries.
Fig. 2. (A) Cumulative proportion of patients with myoclonic seizures during follow-up. Valproate has been highlighted with continuous line and lamotrigine with
discontinuous line. Log-Rank Test: WW = 2.141, Sum = 30.4, Var = 7.1. Test statistic = 2, p = 0.07. (B) Cumulative proportion of patients with tonicclonic seizures during
follow-up. Valproate has been highlighted with continuous line and lamotrigine with discontinuous line. Log-Rank Test: WW = 0.56, Sum = 37.1, Var = 9.2. Test statistic = .18,
p = 0.85. (C) Cumulative proportion of patients with absence seizures during follow-up. Valproate has been highlighted with continuous line and lamotrigine with
discontinuous line. Log-Rank Test: WW = 0.51, Sum = 35.2, Var = 8.2. Test statistic = .16, p = 0.75.
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
852
Table 4
Number of seizures during follow-up and time from randomization to withdrawal
for any reason and to achieve EEG normalization.
Seizure types
Time to withdrawal
Total seizures after
3 months treatment
Total seizures after
6 months treatment
Total seizures after
24 months treatment
Time to achieve EEG
normalization (weeks)
p > 0.05.
Refers to 2 patients (4.8%) that continued with polyspikes and spikes and
waves at the end of the study in the LTG vs. 0 (0%) in the valproate group (per
protocol analysis).
yy
Fig. 3. (A) Cumulative proportion of patients with any seizure type during follow-up according to group of randomization. Cumulative Proportion of patients with seizures
(KaplanMeier curve). Log-Rank Test: WW = 2.01, Sum = 29.4, Var = 5.2.Test statistic = 1.6, p = 0.09. Eight (19.1%) patients randomized to lamotrigine and 6 (19.4%) to
valproic acid were not seizure free after 4 months treatment. (B) Quality of life at the beginning and after 2 years treatment with valproate. Mean, Mean SD, Mean 1.96*SD
(before treatment, rst bars vs. 2 years after treatment, second bars). (1) Total QOLIE, (3) seizure worry, (5) global QOLIE, (7) emotional well-being, (9) energy/fatigability, (11)
cognition functioning, (13) side effects of medication, (15) social functioning. Statistical test: Wilcoxon Matched Pairs Test (*mean p > 0.05, mean 0.05 < p > 0.01, p < 0.01). (C)
Quality of life at the beginning and after 2 years treatment with lamotrigine. Mean, Mean SD, Mean 1.96*SD (before treatment, rst bars vs. 2 years after treatment, second bars).
(1) Total QOLIE, (3) seizure worry, (5) global QOLIE, (7) emotional well-being, (9) energy/fatigability, (11) cognition functioning, (13) side effects of medication, (15) social
functioning. Statistical test: Wilcoxon Matched Pairs Test (*mean p > 0.05, mean 0.05 < p > 0.01, p < 0.01). Global quality of life [valproate vs. lamotrigine; Mean SD]
[45.7 20.1 vs. 73.9 15.5; p = 0.000 (t-test)]. Cognitive functioning [valproate vs. lamotrigine; Mean SD] [58.8 26.5 vs. 79 11.8; p = 0.01 (t-test)].
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
LTG (%)b
Valproate (%)b
3 (7.3)
38 (92.7)
2 (6.5)
29 (93.5)
7 (17.03)
1 (2.4)
3(7.3)
0
1(2.4)
1(2.4)
0
1(2.4)
0
0
0
0
0
1(2.4)
0
1(2.4)
4(9.8)yy
0
0
0
0
11 (35,3)a
2(6.4)
1(3.2)
1(3.2)
0
1(3.2)
5 (16.1)
3 (9.7)
1(3.2)
2(6.4)
3 (9.7)
2(6.4)
2(6.4)
1(3.2)
1(3.2)
0
0
2 (6.4)
1(3.2)
2(6.4)
9 (29.1)
a
Difference of adverse events presentation between drugs: chi squared
test = 1.65; p = 0.03.
b
Percentages are referred to the total of patients per group.
yy
Symbol is referred to the presentation of Stevens Johnson rash in two patients.
Lamotrigine
Valproate
7.3
10.4
9.3
12.5
5.3
27.1
10.9
12.3
14.3
11.7
12.5
11.4
35
8.3
853
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
854
LTG. As for the other patients, the delay in their diagnosis may be
related to a benign clinical presentation, although the combination
of seizure types was similar in patients with or without delayed
diagnosis.35 These variables could have played a role in our study,
too.
One of the most important biases of our study could be that it
was conducted by physicians in a tertiary center. Nevertheless,
none of our patients was refractory to antiepileptic drugs, the
electroclinical characteristics were typical of JME, the men/female
ratio was similar to other studies3537 and the population in our
tertiary center is not different from that of secondary or primary
centers, because of the organization of health care in Cuba. For that
reason, our study mainly reects community based studies.
Another important concern is the power of the sample size
calculation. In line with the objective of the more recent studies,
our study is dedicated to demonstrate equivalence between
lamotrigine and valproate. The design of equivalence trials differs
from that of the traditional studies, aiming to detect differences in
many important aspects. Fundamentally, instead of the conventional test for signicance, statistical analysis is based on
condence intervals (CIs) that dene a range for the possible true
difference between the drugs.1,38 Taking this paradigm into
account, the two drugs under study can be regarded as equivalent
if the entire CI for their difference lies within the pre-set clinically
relevant range of equivalence. In our study we did not nd
differences between lamotrigine and valproate, considering CI for
different primary end points (time to reach 50% of seizure control,
time to withdrawal for any cause and time to achieve remission
according to group of randomization). That is why, although we did
not analyze the power of sample size calculation, this concern is
mitigated by the objective of our investigation.
One of the most important cautions in prescribing lamotrigine
in JME is the probability of myoclonic seizure worsening. This
exacerbation in seizure rate, especially for myoclonic seizures, was
reported by Fernando-Dongas et al.39 and Biraben et al.3 The later
authors reported seven patients with myoclonus exacerbated by
treatment with lamotrigine (LTG), four of whom were taking LTG
monotherapy. This observation and our present results, where 1
(2.4%) of the patients experienced worsening of his seizure rate,
raise concerns about the rationale of using LTG in the treatment of
JME.
Because of possible hair loss, weight gain, and menstrual
irregularities with valproate treatment, many physicians have
used LTG as a rst-line therapy in women with JME. Our positive
experience with the drug contrasts with that reported by Biraben
et al.3 and slightly reects the retrospective study of 24 patients
with an established diagnosis of JME conducted by Carrazana
et al.10 In the Carrazana study seizure control was excellent
(seizure freedom), although two of the 24 patients developed a
dramatic exacerbation of myoclonus, leading to LTG therapy
discontinuation.37 An additional two patients had a mild increase
in morning myoclonus, but it was transient, and sporadic GTCS
continued in 2/24 patients (8.3%). In one patient, the occurrence of
sporadic seizures was attributed to poor therapy compliance.
Other investigators have reported similar positive experiences
with the use of LTG for JME treatment.40 The differences in the
reported experience with LTG in JME may be due to a recruitment
bias.
We agree that further studies are needed to establish the degree
of efcacy and tolerability of LTG in the treatment of JME patients.
We believe that, in the light of certain side effects of VPA treatment
in female patients, LTG should be considered as an alternative
option. Our experience suggests that exacerbation of myoclonus is
seen in a small number of patients.
This observation is not in contradiction with the reports of a
possible exacerbation of myoclonic seizures caused by LTG,
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.
855
Downloaded from ClinicalKey.com at ClinicalKey Global Guest Users August 17, 2016.
For personal use only. No other uses without permission. Copyright 2016. Elsevier Inc. All rights reserved.